Abstract In a prospective, double-blind controlled study we have compared the prophylactic efficacy against deep vein thrombosis of low-dose heparin + dihydroergotamine (A), low molecular weight heparin + dihydro-ergotamine (B) and placebo (C). A total of three hundred and fifty-six patients undergo
β¦ LIBER β¦
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin
β Scribed by G. F. Handeland; U. Abildgaard; H. A. Holm; K. E. Arnesen
- Publisher
- Springer
- Year
- 1990
- Tongue
- English
- Weight
- 645 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Heparin/dihydroergotamine for venous thr
β
Dr. M. R. Lassen; L. C. Borris; H. M. Christiansen; F. MΓΈller-Larsen; V. E. Knud
π
Article
π
1988
π
John Wiley and Sons
π
English
β 495 KB
π 2 views
Cost-minimization analysis of low-molecu
β
Elenir B. C. Avritscher; Scott B. Cantor; Ya-Chen T. Shih; Carmelita P. Escalant
π
Article
π
2004
π
Springer-Verlag
π
English
β 154 KB
Low molecular weight heparin compared wi
β
M. Samama Professor; P. Bernard; J. P. Bonnardot; Sophie Combe-Tamzali; Y. Lanso
π
Article
π
1988
π
John Wiley and Sons
π
English
β 500 KB
Comparison of a low molecular weight hep
β
The European Fraxiparin Study (EFS) Group; Professor A. Encke; Professor K. Bred
π
Article
π
1988
π
John Wiley and Sons
π
English
β 718 KB
Comparison of the cost of preventing pos
β
Professor D. Bergqvist; B. Lindgren; T. MΓ€tzsch
π
Article
π
1996
π
John Wiley and Sons
π
English
β 565 KB
Home treatment of deep venous thrombosis
β
Enric Grau; Jose M. Tenias; Esperanza Real; Jose Medrano; Rosario Ferrer; Emilio
π
Article
π
2001
π
John Wiley and Sons
π
English
β 37 KB
π 2 views
## Abstract Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH) seems as safe and effective as inpatient treatment with unfractionated heparin (UFH). However, most of the randomized trials comparing a LMWH with UFH described clinical outcomes within 3β6 mon